Niagen Bioscience Inc cash flow to debt ratio of 477.00% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Niagen Bioscience Inc's free cash flow has increased 10.04% from $11.95M last year to $13.14M, signaling increasing performance

Niagen Bioscience Inc's debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Niagen Bioscience Inc's debt has decreased relative to shareholder equity from 0.06 last year to 0.03 today, signaling strengthened financials

Niagen Bioscience Inc has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Niagen Bioscience Inc earns at least as much interest as it pays. Interest obligations are fully covered.

Niagen Bioscience Inc's profit margin has increased (66.47%) in the last year from 8.58% to 14.29%, signaling increasing performance

Niagen Bioscience Inc's short-term assets of $96.81M exceed its short-term liabilities of $19.92M

Niagen Bioscience Inc's return on assets of 16.30% is higher than the 5.00% threshold, indicating efficient asset utilization

Niagen Bioscience Inc's return on equity of 25.38%, is higher than 15.00%, indicating good performance

Niagen Bioscience Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Niagen Bioscience Inc had positive net income in only 2.00 out of 5 years, indicating unstable earnings

Niagen Bioscience Inc has positive free cash flow, indicating the company generates cash after capital expenditures

Niagen Bioscience Inc has a free cash flow yield of 5.02%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Niagen Bioscience Inc's yearly earnings has increased 103.30% since last year from $8.55M to $17.38M, signaling increasing performance

Niagen Bioscience Inc's yearly revenue has increased 29.95% since last year from $99.60M to $129.42M, signaling increasing performance

ROIC 11.35% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Niagen Bioscience Inc's 3-year revenue CAGR of 21.56% is positive, indicating growing revenue over the past 3 years

Niagen Bioscience Inc had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Niagen Bioscience Inc had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity

Niagen Bioscience Inc has insufficient data to evaluate this check.

Niagen Bioscience Inc has an earnings yield of 7.09%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Niagen Bioscience Inc is overvalued relative to its fair value price of 2.16 based on EBITDA multiple model

Niagen Bioscience Inc has an EV/EBITDA ratio of 10.19x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Niagen Bioscience Inc is overvalued relative to its fair value price of -1.96 based on Earnings Fair Value model

Niagen Bioscience Inc has a PEG-ratio under 1 which is considered undervalued

Niagen Bioscience Inc has a price-to-book ratio of 3.19x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Niagen Bioscience Inc has a price-to-sales ratio of 2.02x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue